Key facts
- This page summarizes Anne-Virginie Eggimann's Form 4 filing for Codiak BioSciences, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Jun 2022, 16:48.
Anne-Virginie Eggimann - 17 Jun 2022 Form 4 Insider Report for Codiak BioSciences, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2022, 16:48:01 UTC
- Prior SEC filing
- 03 Feb 2022
- Next SEC filing
- 14 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yalonda Howze, Attorney-in-Fact for Anne-Virginie Eggimann
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anne-Virginie Eggimann filed Form 4 for Codiak BioSciences, Inc. on 21 Jun 2022.
Change
- Previous filing in this sequence was filed on 03 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDAKQ
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +7,500
- Change %
- Price
- $0.000000
- Shares after
- 7,500
- Date
- 17 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $2.83
- Footnotes
- F1
CDAKQ
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +1,500
- Change %
- Price
- $0.000000
- Shares after
- 1,500
- Date
- 17 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,500
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F3
On June 17, 2022, the reporting person was granted 1,500 restricted stock units, which shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders.